<DOC>
	<DOCNO>NCT00501293</DOCNO>
	<brief_summary>To evaluate long-term , safety Methylphenidate Transdermal System ( MTS ) age 13-17 year diagnose withADHD</brief_summary>
	<brief_title>Evaluate Safety Efficacy Methylphenidate Transdermal System ( MTS ) Adolescents Aged 13-17 Years With ADHD</brief_title>
	<detailed_description>To evaluate long-term , safety Methylphenidate Transdermal System ( MTS ) symptomatic treatment adolescent age 13-17 year diagnose Attention-Deficit/Hyperactivity Disorder ( ADHD ) Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSM-IV-TR ) criterion . The evaluation safety base treatment-emergent adverse event ( TEAEs ) , laboratory test , vital sign , physical examination , electrocardiogram ( ECGs ) , skin tolerability MTS base dermal response score ( DRS ) .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>To eligible inclusion , subject must fulfill follow criterion Entry visit : The subject participate antecedent SPD485409 study , ) complete require study visit ( Baseline Visit 9 ) OR b ) complete 5 week Dose Optimization period without achieve acceptable condition define antecedent SPD485409 study . Subject blood pressure measurement within 95th percentile age , gender , height Entry . Subject 's ECG result within normal range clinically significant Entry judge Investigator conjunction central reader . Females must negative urine pregnancy test Entry agree use acceptable contraceptive throughout study period 30 day last dose IP . Subject parent legally authorize representative ( LAR ) able , willing likely fully comply study procedure restriction . Written , sign date informed consent participate study must give subject 's parent LAR , accordance International Conference Harmonisation ( ICH ) , Good Clinical Practices ( GCP ) Guideline E6 applicable regulation , complete studyrelated procedure . There must documentation subject 's assent participate study indicate subject aware investigational nature study require procedure restriction . Failure object consider assent . Exclusion Criteria Subjects exclude study follow criterion meet Entry : Subject discontinue SPD485409 due protocol violation , noncompliance , AE , serious adverse event ( SAE ) . Subject concurrent chronic acute illness ( severe allergic rhinitis infectious process require antibiotic ) , disability , condition might confound result safety assessment administer study might increase risk subject . Similarly , subject exclude additional condition ( ) Investigator 's opinion would prohibit subject completing study would best interest subject . This would include significant illness unstable medical condition could lead difficulty comply protocol . Mild , stable asthma exclusionary . Subject take medication exclude . Female subject pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>